Head-to-head · Cost-Efficiency Index
LifespanningRx vs Mevo Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
LifespanningRx
Cost-first shoppers who want longevity/recovery peptide shoppers, not GLP-1 weight-loss shoppers specifically -- likely a non-fit for this list.
Visit LifespanningRxMevo Health
Cost-first shoppers who want a named physician-led provider network, if the quarterly/six-month prepay needed to hit the advertised floor price works for you.
Visit Mevo HealthThe verdict
LifespanningRx and Mevo Health tie on the Cost-Efficiency Index at 53/100, so neither wins outright on the numbers. For most shoppers we'd start with LifespanningRx (ranked #374, a hair above #376) — Cost-first shoppers who want longevity/recovery peptide shoppers, not GLP-1 weight-loss shoppers specifically -- likely a non-fit for this list. But Mevo Health is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs LifespanningRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | LifespanningRx | Mevo Health |
|---|---|---|
| Cost-Efficiency Index | 53/100 | 53/100 |
| Semaglutide / mo | Not disclosed | $199/mo (starting dose, compounded) |
| Tirzepatide / mo | Not disclosed | $259/mo (starting dose, quarterly plan, compounded) |
| Semaglutide / yr (modeled) | — | $2,388 |
| Tirzepatide / yr (modeled) | — | $3,108 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Compounded only |
| Rank here | #374 | #376 |
LifespanningRx
53/100Where the value is
- Broad 48-state+ coverage claim
- Claims LegitScript certification (unverified visually)
- Wide peptide catalog for longevity/recovery use cases
The tradeoffs
- No semaglutide or tirzepatide named anywhere on the public site -- likely miscategorized as a GLP-1 provider
- No pricing disclosed for any product
Mevo Health
53/100Where the value is
- Named, board-certified Medical Director (Dr. David Wasef) heading a stated provider network
- LegitScript verification badge displayed
- Publishes the FDA compounded-medication disclaimer verbatim
The tradeoffs
- The advertised 'as low as $199' / 'as low as $259' floors sit next to monthly/quarterly/six-month plan options with no page clarifying which term unlocks the low price
- No pharmacy partner named — only unlabeled '503A U.S. compounding pharmacy' logos, not independently re-confirmed here
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.